Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Beyond the Birthrate: The Societal Costs of Maternal Mortality
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:
- The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
- The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
- Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
- How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
- and more!
Recent Videos
Related Content
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Podcast
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
